This is a paper by scientists supporting the usage of blood biomarkers in clinical trials instead of spinal fluid and PET scans.


https://link.springer.com/article/10.14283/jpad.2023.68


Here is the abstract. Masters is one of the authors.

J Prev Alzheimers Dis

. 2023;10(3):418-425.

doi: 10.14283/jpad.2023.68.

Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force

D Angioni ¹, O Hansson, R J Bateman, C Rabe, M Toloue, J B Braunstein, S Agus, J R Sims, T Bittner, M C Carrillo, H Fillit, C L Masters, S Salloway, P Aisen, M Weiner, B Vellas, S Gauthier

Affiliations expand

• PMID: 37357282

DOI: 10.14283/jpad.2023.68

Abstract

In randomized clinical trials (RCTs) for Alzheimer's Disease (AD), cerebrospinal fluid (CSF) and positron emission tomography (PET) biomarkers are currently used for the detection and monitoring of AD pathological features. The use of less resource-intensive plasma biomarkers could decrease the burden to study volunteers and limit costs and time for study enrollment. Blood-based markers (BBMs) could thus play an important role in improving the design and the conduct of RCTs on AD. It remains to be determined if the data available on BBMs are strong enough to replace CSF and PET biomarkers as entry criteria and monitoring tools in RCTs.